With offices in New York, Washington, DC; Hartford, Connecticut and San Francisco, Axinn maintains a specialty focus on litigation, particularly of the antitrust and intellectual property varieties. One appreciative client addresses the firm as “excellent, very accessible, responsive and reasonably priced.” This client goes on to note that “Axinn is also more diverse than most IP firms. ‘More diverse’ meaning not all white men and women.”
Operating in the DC office, Aziz Burgy defended Par Pharmaceutical in four separate suits filed by Horizon Therapeutics in various jurisdictions involving a generic version of the drug Ravicti. Collectively, the cases involved six different patents. The four lawsuits and inter partes reviews have all been dismissed and/or terminated in light of a favorable settlement, which grants Par a non-exclusive, perpetual, royalty-free license to manufacture generic Ravicti after July 1, 2025 or earlier under certain conditions. The July 2025 License Effective Date represents allows Par to enter the market nearly a decade before the latest expiring patents directed to Ravicti. Burgy also acts for Par in several other patent matters.